BACKGROUND: Results from apparently conclusive meta-analyses may be false. A limited number of events from a few small trials and the associated random error may be under-recognized sources of spurious findings. The information size (IS, i.e. number of participants) required for a reliable and conclusive meta-analysis should be no less rigorous than the sample size of a single, optimally powered randomized clinical trial. If a meta-analysis is conducted before a sufficient IS is reached, it should be evaluated in a manner that accounts for the increased risk that the result might represent a chance finding (i.e. applying trial sequential monitoring boundaries). METHODS: We analysed 33 meta-analyses with a sufficient IS to detect a treatment effect of 15% relative risk reduction (RRR). We successively monitored the results of the meta-analyses by generating interim cumulative meta-analyses after each included trial and evaluated their results using a conventional statistical criterion (alpha = 0.05) and two-sided Lan-DeMets monitoring boundaries. We examined the proportion of false positive results and important inaccuracies in estimates of treatment effects that resulted from the two approaches. RESULTS: Using the random-effects model and final data, 12 of the meta-analyses yielded P > alpha = 0.05, and 21 yielded P </= alpha = 0.05. False positive interim results were observed in 3 out of 12 meta-analyses with P > alpha = 0.05. The monitoring boundaries eliminated all false positives. Important inaccuracies in estimates were observed in 6 out of 21 meta-analyses using the conventional P </= alpha = 0.05 and 0 out of 21 using the monitoring boundaries. CONCLUSIONS: Evaluating statistical inference with trial sequential monitoring boundaries when meta-analyses fall short of a required IS may reduce the risk of false positive results and important inaccurate effect estimates.
BACKGROUND: Results from apparently conclusive meta-analyses may be false. A limited number of events from a few small trials and the associated random error may be under-recognized sources of spurious findings. The information size (IS, i.e. number of participants) required for a reliable and conclusive meta-analysis should be no less rigorous than the sample size of a single, optimally powered randomized clinical trial. If a meta-analysis is conducted before a sufficient IS is reached, it should be evaluated in a manner that accounts for the increased risk that the result might represent a chance finding (i.e. applying trial sequential monitoring boundaries). METHODS: We analysed 33 meta-analyses with a sufficient IS to detect a treatment effect of 15% relative risk reduction (RRR). We successively monitored the results of the meta-analyses by generating interim cumulative meta-analyses after each included trial and evaluated their results using a conventional statistical criterion (alpha = 0.05) and two-sided Lan-DeMets monitoring boundaries. We examined the proportion of false positive results and important inaccuracies in estimates of treatment effects that resulted from the two approaches. RESULTS: Using the random-effects model and final data, 12 of the meta-analyses yielded P > alpha = 0.05, and 21 yielded P </= alpha = 0.05. False positive interim results were observed in 3 out of 12 meta-analyses with P > alpha = 0.05. The monitoring boundaries eliminated all false positives. Important inaccuracies in estimates were observed in 6 out of 21 meta-analyses using the conventional P </= alpha = 0.05 and 0 out of 21 using the monitoring boundaries. CONCLUSIONS: Evaluating statistical inference with trial sequential monitoring boundaries when meta-analyses fall short of a required IS may reduce the risk of false positive results and important inaccurate effect estimates.
Authors: Michael Walsh; Fausta Catapano; Wladimir Szpirt; Kristian Thorlund; Annette Bruchfeld; Loic Guillevin; Marion Haubitz; Peter A Merkel; Chen Au Peh; Charles Pusey; David Jayne Journal: Am J Kidney Dis Date: 2010-12-30 Impact factor: 8.860
Authors: Kim M Nielsen; Ann-Dorthe Zwisler; Rod S Taylor; Jesper H Svendsen; Jane Lindschou; Lindsey Anderson; Janus C Jakobsen; Selina K Berg Journal: Cochrane Database Syst Rev Date: 2019-02-12
Authors: Lars H Lundstrøm; Christophe Hv Duez; Anders K Nørskov; Charlotte V Rosenstock; Jakob L Thomsen; Ann Merete Møller; Søren Strande; Jørn Wetterslev Journal: Cochrane Database Syst Rev Date: 2017-05-17
Authors: Christian S Meyhoff; Jørn Wetterslev; Lars N Jorgensen; Steen W Henneberg; Inger Simonsen; Therese Pulawska; Line R Walker; Nina Skovgaard; Kim Heltø; Peter Gocht-Jensen; Palle S Carlsson; Henrik Rask; Sharaf Karim; Charlotte G Carlsen; Frank S Jensen; Lars S Rasmussen Journal: Trials Date: 2008-10-22 Impact factor: 2.279